Based on the urgent demand for new drugs in the market, we plan to collaborate with other relevant companies, research institutions, and investors to jointly drive the research and market launch of the anti-SIAH1 inhibitors.
Although we have been approached by several Angel funding, we are still in the process of seeking Angel funding to facilitate the process of new drug development of anti-SIAH1 inhibitors.
Company Profile
Since the discovery of small molecule compounds that can achieve effective neural regeneration, Dr. Kou-Juey Wu has founded Pharwar Pharmaceuticals, Inc. and filed patent applications (US provisional 63/358,954, PCT CN2023/088337, CN2023/092881). The company currently owns the exclusive patent rights of these unique small molecule compounds.